Patients from 22+ countriesPlan your visit →
lutetium-therapy
Considering Lu-177 Therapy · 3 Sept 2026

Lu-177 PSMA Therapy After 75: What the Evidence Shows

There is no official upper age limit for Lu-177 PSMA therapy. What actually determines eligibility for older men with mCRPC is kidney function, bone marrow reserves, PSMA expression on a PET scan, and general fitness - not your age in years.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 3 Sept 2026
Lu-177 PSMA Therapy After 75: What the Evidence Shows

Lu-177 PSMA therapy treats metastatic castration-resistant prostate cancer (mCRPC) in men. If you've been told you're too old for this treatment, the evidence suggests otherwise.

Lu-177 PSMA therapy has no official upper age limit. The FDA approved lutetium Lu-177 vipivotide tetraxetan (Pluvicto) for adults with PSMA-positive mCRPC. Age doesn't matter - what matters is whether your tumors show enough PSMA on a PET scan and whether your kidneys and bone marrow are healthy enough to handle the treatment safely.

This matters for older men. A 78-year-old with good kidney function and good energy may be a better candidate than a 63-year-old with organ problems. Seeing the real difference helps you ask the right questions.

What "Too Old" Usually Means in Clinical Terms

When a doctor says age is a concern, it usually means something else: kidney function, bone health, and fitness level matter more than your birth year.

Doctors assess your fitness using a tool called ECOG performance status. It runs from 0 (fully active) to 5 (unable to care for yourself). ECOG 1 means you can do light tasks but get tired easily. ECOG 2 means you rest more than half the day but can still care for yourself. Most Lu-177 PSMA therapy trials required ECOG 0 or 1. But real-world programs treated ECOG 2 patients and found benefit - mostly when cancer, not other health problems, caused the fatigue.

The key point: ECOG shows what your body can do today, not the years you've lived. Both can change.

Who Was in the VISION Trial?

VISION was a large phase 3 study that proved Lu-177 PSMA therapy works for mCRPC. It led to FDA approval in March 2022.

VISION study results show that patients getting Lu-177 PSMA had an average age of 71, with most between 65 and 75. Many men in their 70s were enrolled and helped show the treatment works for survival and stopping cancer growth. The FDA approval has no age limit.

VISION patients had to have tried at least one hormone therapy like enzalutamide or abiraterone, and at least one taxane chemotherapy. This means most had already had years of treatment before joining the study. Many were in their late 60s or 70s when they started.

What Real-World Studies Show About Men Over 75

VISION focused on patients 65 and older, so there wasn't much data on men over 75. Since approval, researchers have published real-world studies to fill that gap.

A 2025 study looked at how well Lu-177 PSMA worked in older men. It compared men aged 75 and under with those older than 75. The results were clear: age didn't make a difference in how long they survived or how long before cancer came back.

A separate study focused on age-related outcomes of Lu-177 PSMA therapy in mCRPC and included men aged 80 and above. The authors reported that the therapy worked well and was well tolerated in this very elderly group, if they had good organ function before treatment.

These are observational studies, not randomized trials, so they have limits. But they show the same thing: age alone doesn't determine how well treatment works. Organ function and PSMA expression do.

What Doctors Actually Check Before Treatment

No matter your age, doctors check these things to see if Lu-177 PSMA is right for you.

PSMA Expression on PET Scan

This is the key test. Before anything else, a PSMA-PET scan must show your tumors have enough PSMA protein - usually more than normal liver shows on the scan. If your tumors don't have enough PSMA, you can't get Lu-177 PSMA therapy, no matter how fit you are. For more on how doctors read PSMA-PET scans and what different results mean for next steps, see the full guide.

Kidney Function

The kidneys get radiation during each treatment because the drug leaves your body through urine. Your doctor will check your kidney function (eGFR and creatinine levels) before you start. Mildly reduced kidney function won't automatically stop treatment, but very bad kidney function might limit how many cycles you can have - or make treatment unsafe. This is one of the most common questions for older men. The guide on kidney function and Lu-177 PSMA eligibility has more details.

Bone Marrow Reserves and Blood Counts

Lu-177 PSMA therapy can lower your blood cell counts. Before you start, your doctor checks your platelet count, white blood cell count, and hemoglobin. Standard minimum levels include a platelet count above 75,000 per microliter and a white blood cell count above 3,000 per microliter. Men with widespread bone cancer or many prior treatments may have lower counts - and this is where past treatment can matter more than age.

Long-term hormone therapy (ADT), which most mCRPC patients have had for years, can also reduce bone density over time. If bone health is a concern, talk to your doctor before taking any supplements, as they may interact with treatment.

Liver Function

Standard criteria require liver enzymes - mostly AST and ALT - to be in a normal range. Your doctor checks these before treatment starts and before each cycle. If your levels are too high, it may delay your treatment.

ECOG Performance Status

Doctors assess your activity level using ECOG. Most programs require a score of 0 or 1. Some will accept ECOG 2 on a case-by-case basis, especially when cancer - not other health problems - causes your limitations.

Frailty Matters More Than Your Birth Year

Some cancer centers now use frailty tools - like the G8 screening test or the Clinical Frailty Scale - for patients over 70. These tools check more than activity level. They look at nutrition, weight changes, memory, and mobility. The difference between being old and being frail really matters.

A 76-year-old who is active, eats well, and has good kidneys might be fit for treatment even though their age sounds like a problem. A 68-year-old who has lost weight, has organ damage, and has trouble with daily tasks might struggle more with treatment. Your birth year is not the best predictor.

If your doctor says age is a problem but hasn't ordered organ function tests and a PSMA-PET scan, get a second opinion. You can get a second opinion through Art of Healing Cancer. Their team can review your scans, labs, and treatment history - and discuss other options if Lu-177 PSMA isn't right for you.

When Age-Related Factors Can Complicate Eligibility

Age-related changes can cause real problems sometimes. These aren't always deal-breakers, but they do need careful thought.

  • Significantly reduced kidney function: This is common in older men. If your kidney function is much lower than normal, the radiation dose to your kidneys from each cycle becomes a serious problem. The guide on Lu-177 PSMA for frail patients who can't take chemotherapy covers specialist approaches.
  • Low platelet or white blood cell counts: Widespread bone cancer and many prior treatments can lower your cell counts. Your doctor will weigh this risk against the expected benefit of treatment.
  • Multiple medications: Older men often take drugs for heart disease or diabetes. Your doctor will check for interactions during pre-treatment visits.
  • Difficulty staying hydrated: You need good fluid intake before and after each cycle to protect your kidneys. Some older patients struggle to do this at home and may need extra help.

None of these factors automatically stop treatment. Each one needs careful thought - not a final no.

Practical Steps if You Are an Older Man Considering Lu-177 PSMA

  1. Ask whether your doctor has done or planned a PSMA-PET scan. You need this scan before anyone can really tell if Lu-177 PSMA is right for you.
  2. Request organ function tests. Ask for your kidney function (eGFR and creatinine), blood counts, and liver function results. Bring these to your eligibility appointment.
  3. Ask about your ECOG score or frailty assessment. If your center uses frailty tools for patients over 70, ask if they've tested you and what the score means.
  4. Seek a second opinion if age is the only reason you're told no. A blanket "you're too old" without a scan or current labs isn't a real assessment.
  5. Be honest about your daily abilities. Your doctor needs an accurate picture of what you can do on a normal day. Describing only your best days can lead to a plan that doesn't fit your real situation.

When to Talk to Your Doctor

Talk to your oncologist if you have mCRPC that has progressed on hormone therapy and haven't been assessed for Lu-177 PSMA yet. Ask specifically about PSMA-PET imaging if your doctor hasn't ordered it. If your doctor says age is the main reason you can't have treatment - without checking kidney function, blood counts, and activity level - get a clearer explanation. Age is a starting point for talking with your doctor - not a final answer.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Is there an official age cutoff for Lu-177 PSMA therapy?

No. The FDA approval of lutetium Lu-177 vipivotide tetraxetan covers adult patients with PSMA-positive mCRPC and sets no upper age limit. Eligibility is based on PSMA expression shown on a PET scan, kidney function, bone marrow reserves, and general fitness - not age in years.

Can men over 80 receive Lu-177 PSMA therapy?

Real-world studies have included patients aged 80 and above and found the therapy to be effective and well tolerated in this group, provided organ function criteria were met before starting. These findings come from observational studies rather than clinical trials, so they have limitations - but they consistently suggest that very elderly patients should not be excluded from the eligibility conversation without a proper workup.

What ECOG performance status is needed for Lu-177 PSMA?

Most clinical trials required ECOG 0 or 1. In real-world treatment programs, some patients with ECOG 2 have received the therapy and seen benefit, particularly when their fatigue or functional limitation was caused by the cancer rather than unrelated medical conditions. Your oncologist can help you understand where you currently sit on this scale.

Does kidney disease automatically rule out Lu-177 PSMA therapy?

Not automatically. Mildly reduced kidney function may still be compatible with treatment, though it requires careful monitoring. Significantly impaired kidneys - assessed by eGFR and creatinine levels - may limit how many cycles are safe or may make the therapy inappropriate altogether. A specialist experienced in radioligand therapy can evaluate your specific situation in detail.

My doctor said I am too old for Lu-177 PSMA. What should I do next?

Ask your doctor to name the specific clinical factor causing concern - kidney function, blood counts, ECOG score, or another issue. If no PSMA-PET scan has been done, request one or ask for a referral to a center that performs them. A second opinion from a nuclear medicine or oncology team experienced in Lu-177 PSMA therapy is a reasonable step before accepting that assessment as final.

Does long-term ADT affect Lu-177 PSMA eligibility?

ADT itself does not disqualify you. Continuing ADT alongside Lu-177 PSMA therapy is in fact standard practice. However, long-term ADT can reduce bone density over time and may affect blood counts. These factors are assessed as part of the standard pre-treatment workup, so your team will be looking at them regardless.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Lu-177 PSMA for Older Men: Age, Fitness, Eligibility | lutetium-therapy